Optimizing linkers and conjugation technologies to reduce ADC toxicities
28 Apr 2026
ADC Linker Design & Conjugation Technologies
- How can linker design balance systemic stability, efficient intracellular cleavage, and overall toxicity to prevent premature payload release while maintaining optimal therapeutic efficacy?
- How does drug-to-antibody ratio (DAR) heterogeneity arising from non-site-specific conjugation affect ADC efficacy, pharmacokinetics, aggregation, and off-target toxicity?
- What mechanisms contribute to non-specific target engagement and off-target toxicity in ADCs, despite the use of tumor-targeting antibodies?
- How does conjugation site heterogeneity influence ADC stability, pharmacokinetics, therapeutic index, and dose optimization?
Industry Expert
